Novoprotein Scientific Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	-	647.35	863.7	929.92	189.39
Short-Term Investments	-	1,154	404.51	-	-
Trading Asset Securities	-	-	621.7	966.85	-
Cash & Short-Term Investments	799.16	1,801	1,890	1,897	189.39
Cash Growth	-55.63%	-4.69%	-0.36%	901.50%	101.86%
Accounts Receivable	-	62.02	79.97	134.66	96.58
Other Receivables	-	10.91	3.45	10.35	2.95
Receivables	-	72.93	83.42	145	99.53
Inventory	-	76.08	84.97	77.08	37.19
Other Current Assets	-	5.95	11.9	16.29	6.11
Total Current Assets	-	1,956	2,070	2,135	332.22
Property, Plant & Equipment	-	170.14	133.92	134.98	137.95
Long-Term Investments	-	10	-	-	-
Other Intangible Assets	-	18.21	18.71	18.18	6.71
Long-Term Deferred Tax Assets	-	31.22	27.94	18.51	12.96
Long-Term Deferred Charges	-	10.78	9.69	5.6	4.93
Other Long-Term Assets	-	21.48	38.45	21.05	18.33
Total Assets	-	2,218	2,299	2,333	513.1
Accounts Payable	-	28.26	17.94	20.9	23.64
Accrued Expenses	-	14.82	11.82	18.03	21.21
Current Portion of Leases	-	17.67	13.87	13.95	8.69
Current Income Taxes Payable	-	0.01	1.34	5.01	4.52
Current Unearned Revenue	-	5.02	4.19	4.81	11.61
Other Current Liabilities	-	1.39	0.97	1.32	2.11
Total Current Liabilities	-	67.17	50.12	64.02	71.78
Long-Term Leases	-	48.75	59.44	69.2	78.34
Long-Term Unearned Revenue	-	0.52	0.87	-	-
Long-Term Deferred Tax Liabilities	-	-	-	-	3.21
Total Liabilities	-	116.44	110.43	133.22	153.33
Common Stock	-	70.18	70.18	70.18	52.63
Additional Paid-In Capital	-	1,963	1,950	1,940	208.13
Retained Earnings	-	78.36	167.86	190.1	98.82
Treasury Stock	-	-10.35	-	-	-
Comprehensive Income & Other	-	0.15	0.18	0.18	0.19
Shareholders' Equity	2,080	2,102	2,188	2,200	359.77
Total Liabilities & Equity	-	2,218	2,299	2,333	513.1
Total Debt	48.38	66.42	73.31	83.15	87.04
Net Cash (Debt)	750.78	1,735	1,817	1,814	102.36
Net Cash Growth	-56.73%	-4.50%	0.16%	1671.86%	9.09%
Net Cash Per Share	10.74	24.87	25.46	31.79	2.56
Filing Date Shares Outstanding	68.4	69.83	70.18	70.18	52.63
Total Common Shares Outstanding	69.77	69.83	70.18	70.18	52.63
Working Capital	-	1,889	2,020	2,071	260.44
Book Value Per Share	29.82	30.10	31.19	31.35	6.84
Tangible Book Value	2,063	2,083	2,170	2,182	353.06
Tangible Book Value Per Share	29.56	29.84	30.92	31.09	6.71
Machinery	-	78.93	64.44	59.66	42.2
Construction In Progress	-	74.95	31.26	17.73	21.16

Source: S&P Global Market Intelligence. Standard template. Financial Sources.